Smectite Clay Binds Gluten to Treat Celiac Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for celiac disease rely solely on a restrictive gluten-free diet, which is socially challenging and difficult to maintain, lacking effective medical alternatives for managing symptoms and intestinal damage.
Innovation Solution
The use of a dioctahedral smectite clay, such as montmorillonite or diosmectite, in pharmaceutical compositions to treat and prevent celiac disease, administered orally, which has shown anti-inflammatory and mucosal protective effects in previous studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a gluten-free diet is implemented to treat celiac disease, then clinical cure and prevention of complications is achieved, but social constraints and difficulty in implementation increase
Solution Approach 1:
The patent introduces clay (smectite or montmorillonite) as an intermediary substance that binds to gluten proteins in the gastrointestinal tract, preventing their absorption and harmful effects. This mediator allows patients to take gluten-containing foods without triggering the immune response, thus maintaining treatment effectiveness while eliminating the need for strict dietary restriction.
2Ease of operation
If clay is used to treat celiac disease, then dietary constraints are reduced, but treatment effectiveness needs to be maintained
Solution Approach 1:
Clay acts as a mediator that specifically targets and binds gluten proteins in the gastrointestinal tract. This selective binding prevents gluten absorption and immune activation, allowing patients dietary freedom while maintaining treatment effectiveness through the clay-g gluten interaction rather than dietary restriction.
Solution Approach 2:
The patent replaces the mechanical/dietary control system (strict gluten-free diet requiring patient discipline and dietary management) with a chemical/pharmacological system (clay administration). The clay chemically binds to gluten in the gut, substituting the need for mechanical dietary exclusion with a pharmacological intervention that achieves the same protective effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The smectite clay composition demonstrates potential in reducing digestive symptoms, improving intestinal mucosa health, and normalizing villous atrophy, as evidenced by histological monitoring and clinical studies, offering a viable alternative to dietary exclusion.
Implementation Method 1
The clay used according to the invention can be a clay from the smectite family. Smectites represent a particular family of clays in which we find dioctahedral species such as montmorillonite and beidellite
Implementation Method 2
Gonzalez R. et al., 2004 (British Journal of Pharmacology, 141(6): 951-960) shows the anti-inflammatory effect of diosmectite (dioctahedral smectite) on a model of induced chronic colitis in rats, and suggests a mechanism of action that may involve protein uptake, mucosal protection, and modulation in the production of pro-inflammatory mediators in the colonic mucosa.
Data Source
AI summary
The invention relates to the use of clay for preparing a drug for treating coeliac disease. Preferably, the clay used is of the smectite type.